Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q3 2025 Earnings Presentation
20 slides from Hls Therapeutics's earnings presentation, Nov 13, 2025
Slide 1: Q3 2025 Conference Call
Q3 2025 Conference Call November 13, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Track Record of Growing Profitability and Cash Flow
Track Record of Growing Profitability and Cash Flow CDN Product U.S. Product Operating Revenue Revenue Expenses 2% YTD 1% YTD 20% YTD (in CAD) Adjusted Adjusted Cash from EBITDA EBITDA Operations 25% YTD 87% 121% YTD (since Q3’23*) *excluding royalties Toronto Stock Exchange (TSX) - HLS Provided as
Slide 4: 2025 Guidance Update
2025 Guidance Update Adj. EBITDA Vascepa Clozaril CDA Clozaril U.S. Unchanged Mid-teens % growth (in CAD) 4-5% decrease (in CAD) Unchanged (17-23% growth) (vs 18-26% prior) (vs flat estimate prior) (2-4% decrease) Consolidated revenue estimate of $55-56M* *USD. Includes royalty revenue estimate of $
Slide 5: Building a Cardiovascular Powerhouse
Building a Cardiovascular Powerhouse Three products, one goal: reducing cardiovascular risk for more Canadians Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any
Slide 6: Strengthening our Financial Foundation
Strengthening our Financial Foundation Strong balance Reduced bank New credit sheet and cash debt by 41% agreement with flow increases since Q3 2023 improved terms flexibility for strategic capital allocation Toronto Stock Exchange (TSX) - HLS HLS THERAPEUTICS INC. 6
Slide 7: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 8: Building a Canadian leader in oral cardiovascular risk reduction
Building a Canadian leader in oral cardiovascular risk reduction Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 9: Continued Prescribing Growth
Continued Prescribing Growth TRx Units Since Launch 180000 160000 22% Q3 increase in unit demand* 140000 120000 100000 29% Q3 increase in consistent prescribers* 80000 60000 40000 NRx grew each month in the quarter (yoy) 20000 0 2020 2021 2022 2023 2024 TTM *Compared to Q3 2024 09-30-2025 Vascepa co
Slide 10: Bempedoic Acid: Expanding our Cardiovascular Franchise
Bempedoic Acid: Expanding our Cardiovascular Franchise Overview Value Proposition Clinical Advantages Oral CV medicines Differentiated Mechanism of Action Use with or without a statin FDA approved 2020 (lower LDL-C) Sizable target patient population Not activated in skeletal muscle Label expanded 20
Slide 11: Canadian Market Opportunity
Canadian Market Opportunity ~200K >300K >500K Patients not at target LDL-C Canadians unable to take Canadian levels despite statin/ezetimibe recommended statin therapy patients therapy Source: IQVIA data and primary market research estimates 600-700K patients on statin/ezetimibe therapy of which 30-
Slide 12: Compelling Trial Data
Compelling Trial Data CLEAR OUTCOMES TRIAL RESULTS: CV Risk Reduction Primary Prevention* LDL-C Reduction Nonfatal MI 30% of patients 27% enrolled have not had RRR their first event but are at high risk 38% HR, 0.73 (95% CI: 0.62-0.87) Coronary Revascularization MACE-4 (nonfatal MI, coronary revascu
Slide 13: Launch will Leverage Current CV Infrastructure
Launch will Leverage Current CV Infrastructure Leverage current High overlap with Minimal additional field footprint Vascepa prescribers OpEx required Q4 2025 Q2 2026 2027 Health Canada Commercial launch Public listings approval expected with meaningful private coverage Long patent runway: Vascepa t
Slide 14: Financial Review: Strengthening Foundation to Support Growth
Financial Review: Strengthening Foundation to Support Growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 15: Revenue Growth from Marketed Products
Revenue Growth from Marketed Products YTD Marketed Product Revenue (USD$000’s) 45,000 40,000 35,000 2% YTD growth (in CAD) 30,000 Canadian product sales of Vascepa and Clozaril 25,000 20,000 15,000 1% YTD growth (in USD) 10,000 US sales of Clozaril 5,000 0 YTD 2024 YTD 2025 Toronto Stock Exchange (T
Slide 16: Reducing Expenses, Improving Margins & Generating Cash Flow
Reducing Expenses, Improving Margins & Generating Cash Flow YTD Operating Expenses YTD Adj. EBITDA YTD Cash from Operations (excluding Cost of Sales) ($000’s) (excluding Royalties) ($000’s) ($000’s) 24,000 14,000 22,000 10,000 12,000 20,000 18,000 10,000 8,000 16,000 14,000 8,000 6,000 12,000 20% 25
Slide 17: Operational Changes Delivering Improved Profitability
Operational Changes Delivering Improved Profitability Adj EBITDA ex Royalties 20000 (trailing twelve month basis) 18000 16000 14000 12000 $(000s) 10000 87% 8000 6000 4000 2000 0 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Toronto Stock Exchange (TSX) - HLS Provided as par
Slide 18: De-levering and Strengthening the Balance Sheet
De-levering and Strengthening the Balance Sheet Summary Balance Sheet & Capitalization Net Debt (US$ millions) 80 (US$ millions) At Dec 31, 2024 At Sept 30, 2025 70 Cash and Cash Equivalents 17.5 10.8 1 60 Senior Secured Term Loan 67.4 53.1 50 Net Debt (Term Loan less Cash) 50.0 43.5 40 42% 30 20 At
Slide 19: YTD Summary
YTD Summary 1 Consistent Profitability (Adj. EBITDA) Growth: 25% YTD, 87%* since Q3 2023 2 Strong Cash Generation: cash from operations up 121% YTD 3 CV Salesforce Transition Complete: fully deployed team in place 4 Growth Catalyst in Place: Q2 2026 target launch for Bempedoic Acid 5 New Credit Agre
Slide 20: Q3 2025 Conference Call
Q3 2025 Conference Call November 13, 2025 Craig Millian, CEO John Hanna, CFO Brian Walsh, CCO TSX - HLS